Shielding Normal Cells, Precisely Targeting Cancer Cells!
Safeguarding normal cells from treatments and make them work selectively for cancer cells onlythrough a targeting technology.
through a targeting technology.
THE SCIENCE
Our Science foundation is based on understanding of how Cancer cells bypass treatments irrespective of nature of treatments and do exactly opposite to cancer tactics.
We achieve it for patients with our technology “ A priori Activation of Apoptosis Pathways of Tumor” (AAAPT).
OUR APPROACH
Our approach is to reduce the side effects of current treatments and make them effective at lower doses or all cancers.
Chemotherapy can be an effective cancer treatment, but it may also harm healthy cells, including stem cells. To mitigate this risk, our technology can be used to target tumor cells while protecting healthy stem cells.
Our AAAPT Technology
AAAPT Technology refers to ” A Priori Activation of Apoptosis Pathways of Tumor” which prepares non-responding cancer cells to induce cell death by the current treatments. In the absence of AAAPT, cancer stem cells (CSCs) and cancer resistant cells (CRCs) will escape cell death and make the treatments ineffective and raises side effects. AAAPT is designed to target cancer cells while sparing normal cells. It works by activating specific cell death pathways and inhibiting survival pathways in cancer cells. Our research has shown that using AAAPT in combination with doxorubicin can sensitize various types of cancer cells and reduce the amount of doxorubicin needed in vitro. At higher doses, AAAPT can also act as an anti-tumor agent on its own. This study suggests that AAAPT could be used as a neoadjuvant to chemotherapy to enhance its efficacy and reduce off-target toxicity when used in conjunction with doxorubicin.
Benefits Of Our AAAPT Technology
Resistance Prevention
Combination Therapy Potential
Minimal Systemic Toxicity
Potential for Long-term Remission
Resistance Prevention
Resistance Prevention
Some cancer cells develop resistance to traditional treatments over time. AAAPT technology can offer a solution by targeting apoptosis pathways that are less susceptible to resistance mechanisms employed by cancer cells.Combination Therapy Potential
Combination Therapy Potential
AAAPT technology can be combined with other cancer treatments, such as chemotherapy, immunotherapy, or targeted therapy, to enhance their efficacy.Minimal Systemic Toxicity
Minimal Systemic Toxicity
Because AAAPT technology selectively targets cancer cells, it may result in lower systemic toxicity compared to conventional treatmentsPotential for Long-term Remission
Potential for Long-term Remission
By effectively inducing apoptosis in cancer cells, AAAPT technology has the potential to achieve long-term remission. This could significantly improve the prognosis for patients with various types of cancer.Meet Raghu S. Pandurangi
Founder, President-CSO at Sci-Engi-Medco solutions Inc and Amplexi-LLC
Dr. Raghu Pandurangi is a clinical scientist with extensive experience in oncology drug development, biomarkers imaging, and translational medicine. With over three decades of experience in cancer diagnosis and therapy, Dr. Raghu Pandurangi and his team have developed the AAAPT technology to enhance the clinical utility of chemotherapy and other treatments by reducing the side effects. He has contributed significantly to the field with 53 publications, > 150 presentations (> 70 Invited) including many key note presentations and chairing the sessions, 59 oral presentations at scientific meetings (31 of which were invited), Developed two FDA approved products, AccuTect and NeoTect, one product development course for marketing personnel, 15 collaborations, 19 patent disclosures, 4 book chapters, and 1.5 million dollars in academic funding. As a President of SEMCO, generated more than 1 million 4 SBIR-NIH grants and instrumental in bringing the technology to IND level.
Play Video